Comparison of epidemiological characteristics and prevention of breast cancer in China and the United States_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XIONG Jie , DUAN Zhicai ,  ZUO Huaiquan

1. Department of Breast Surgery, Sichuan Provincial Center for Gynaecology and Breast Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P. R. Chinaa;

Corresponding author：

ZUO Huaiquan, Email: 13982772996@163.com

Keywords：

female breast cancer; incidence; mortality; risk factor; prevention

DOI：

10.7507/1007-9424.202311024

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective By comparing the epidemiological characteristics of the incidence and death of female breast cancer in China and the United States, the differences in prevention and screening strategies between China and the United States were analyzed to explore the prevention and control measures of female breast cancer in China. Methods Based on the relevant data released by the Global Burden of Disease in 2020, the National Cancer Center of China, and the China Health Statistical Yearbook, the new cases and deaths of breast cancer in Chinese and American women in 2023 were estimated respectively, and the incidence, mortality and time trend of breast cancer in Chinese and American women were analyzed. Results In China, 376 789 new cases of female breast cancer and 116 791 deaths were expected in 2023. In the United States, approximately 297 790 women were expected to be newly diagnosed with breast cancer in 2023, representing approximately 15.2% of new cancer cases. About 43 170 women died from breast cancer, accounting for about 7.1% of all cancer deaths. The incidence of breast cancer in women in the United States during the period 1975–2020 gradually increased and then stabilized; In contrast, the incidence of breast cancer among Chinese women increased year by year during the period 1990–2020. In recent years, the incidence and mortality rates of breast cancer in Chinese women had increased more than those in the United States, and there was a large difference between urban and rural areas in China. Conclusions Both China and the United States face a large burden of female breast cancer, and the characteristics of female breast cancer in China are similar to those in the United States. To reduce the burden of breast cancer in Chinese women, further efforts should be made in various aspects, such as strengthening breast cancer education, raising public health awareness, improving diet structure, cultivating healthy lifestyle, increasing screening efforts, and improving medical level.

Citation： XIONG Jie, DUAN Zhicai, ZUO Huaiquan. Comparison of epidemiological characteristics and prevention of breast cancer in China and the United States. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(1): 50-55. doi: 10.7507/1007-9424.202311024 Copy

1.	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
2.	Lin L, Li Z, Yan L, et al. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol, 2021, 14(1): 197. doi: 10.1186/s13045-021-01213-z.
3.	Peng Z, Wei J, Lu X, et al. Treatment and survival patterns of Chinese patients diagnosed with breast cancer between 2005 and 2009 in Southwest China: an observational, population-based cohort study. Medicine (Baltimore), 2016, 95(25): e3865. doi: 10.1097/MD.0000000000003865.
4.	Lou Z, Fei X, Christakos G, et al. Improving spatiotemporal breast cancer assessment and prediction in Hangzhou City, China. Sci Rep, 2017, 7(1): 3188. doi: 10.1038/s41598-017-03524-z.
5.	Barrios CH, Reinert T, Werutsky G. Global breast cancer research: moving forward. Am Soc Clin Oncol Educ Book, 2018, 38: 441-450.
6.	Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015. JNCC, 2021, 1(1): 2-11.
7.	Howlader N, Noone AM, Krapcho M, et al (eds). SEER cancer statistics review, 1975–2018, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2018/, based on November 2020 SEER data submission, posted to the SEER web site, April 2021.
8.	Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019, 144(8): 1941-1953.
9.	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
10.	Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin, 2022, 72(6): 524-541.
11.	Davis Lynn BC, Chernyavskiy P, Gierach GL, et al. Decreasing incidence of estrogen receptor-negative breast cancer in the United States: trends by race and region. J Natl Cancer Inst, 2022, 114(2): 263-270.
12.	Sharma R. Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990-2019: an examination using estimates from the global burden of disease 2019 study. Breast Cancer Res Treat, 2023, 202(3): 529-540.
13.	张馨, 吴羡美, 李虹, 等. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担. 实用肿瘤学杂志, 2023, 37(2): 107-111.
14.	胡志强, 游伟程, 潘凯枫, 等. 中、美两国癌症流行特征分析—《2023美国癌症统计报告》解读. 科技导报, 2023, 41(18): 18-28.
15.	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. JNCC, 2022, 2(1): 1-9.
16.	Mahdavi M, Nassiri M, Kooshyar MM, et al. Hereditary breast cancer; Genetic penetrance and current status with BRCA. J Cell Physiol, 2019, 234(5): 5741-5750.
17.	Łukasiewicz S, Czeczelewski M, Forma A, et al. Breast cancer—Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. Cancers (Basel), 2021, 13(17): 4287. doi: 10.3390/cancers13174287.
18.	Huang YJ, Lee PH, Chen LC, et al. Relationships among green space, ambient fine particulate matter, and cancer incidence in Taiwan: a 16-year retrospective cohort study. Environ Res, 2022, 212(Pt C): 113416. doi: 10.1016/j.envres.2022.113416.
19.	Niehoff NM, Terry MB, Bookwalter DB, et al. Air pollution and breast cancer: an examination of modification by underlying familial breast cancer risk. Cancer Epidemiol Biomarkers Prev, 2022, 31(2): 422-429.
20.	Zupunski L, Yaumenenka A, Ryzhov A, et al. Breast cancer incidence in the regions of Belarus and Ukraine most contaminated by the Chernobyl accident: 1978 to 2016. Int J Cancer, 2021, 148(8): 1839-1849.
21.	Landrigan PJ, Raps H, Cropper M, et al. The Minderoo-Monaco Commission on plastics and human health. Ann Glob Health, 2023, 89(1): 23. doi: 10.5334/aogh.4056.
22.	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范 (2021年版). 中国癌症杂志, 2021, 31(10): 954-1040.
23.	中国研究型医院学会乳腺专业委员会, 中国女性乳腺癌预防共识专家组. 中国女性乳腺癌预防专家共识. 中国研究型医院, 2022, 9(4): 5-13.
24.	Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA, 2015, 314(15): 1599-1614.
25.	李爱华, 叶研, 沈壮, 等. 北京市女性乳腺癌绝经前后危险因素分析. 现代预防医学, 2022, 49(13): 2492-2496.
26.	庞晶, 贾斌, 朱慧瑞, 等. 低浓度TBBPA长期暴露对乳腺癌细胞增殖效应研究. 山西大学学报 (自然科学版), [2023-12-14]. http://kns.cnki.net/kcms/detail/14.1105.n.20230708.2116.003.html.
27.	Winters S, Martin C, Murphy D, et al. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci, 2017, 151: 1-32.
28.	Lynch BM, Neilson HK, Friedenreich CM. Physical activity and breast cancer prevention. Recent Results Cancer Res, 2011, 186: 13-42.
29.	Wang F, Liu L, Cui S, et al. Distinct effects of body mass index and waist/hip ratio on risk of breast cancer by joint estrogen and progestogen receptor status: results from a case-control study in Northern and Eastern China and implications for chemoprevention. Oncologist, 2017, 22(12): 1431-1443.
30.	Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press), 2019, 11: 151-164.
31.	Jia T, Liu Y, Fan Y, et al. Association of Healthy Diet and Physical Activity With Breast Cancer: Lifestyle Interventions and Oncology Education. Front Public Health, 2022, 10: 797794. doi: 10.3389/fpubh.2022.797794.
32.	Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin, 2019, 69(3): 184-210.
33.	Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst, 2014, 106(11): dju289. doi: 10.1093/jnci/dju289.
34.	Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med, 2005, 353(17): 1784-1792.
35.	何明艳, 朱碧琪, 钟媛, 等. 2005-2013年中国女性乳腺癌发病及死亡趋势分析. 中华疾病控制杂志, 2019, 23(1): 10-14.

1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
2. Lin L, Li Z, Yan L, et al. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol, 2021, 14(1): 197. doi: 10.1186/s13045-021-01213-z.
3. Peng Z, Wei J, Lu X, et al. Treatment and survival patterns of Chinese patients diagnosed with breast cancer between 2005 and 2009 in Southwest China: an observational, population-based cohort study. Medicine (Baltimore), 2016, 95(25): e3865. doi: 10.1097/MD.0000000000003865.
4. Lou Z, Fei X, Christakos G, et al. Improving spatiotemporal breast cancer assessment and prediction in Hangzhou City, China. Sci Rep, 2017, 7(1): 3188. doi: 10.1038/s41598-017-03524-z.
5. Barrios CH, Reinert T, Werutsky G. Global breast cancer research: moving forward. Am Soc Clin Oncol Educ Book, 2018, 38: 441-450.
6. Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015. JNCC, 2021, 1(1): 2-11.
7. Howlader N, Noone AM, Krapcho M, et al (eds). SEER cancer statistics review, 1975–2018, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2018/, based on November 2020 SEER data submission, posted to the SEER web site, April 2021.
8. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019, 144(8): 1941-1953.
9. Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
10. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin, 2022, 72(6): 524-541.
11. Davis Lynn BC, Chernyavskiy P, Gierach GL, et al. Decreasing incidence of estrogen receptor-negative breast cancer in the United States: trends by race and region. J Natl Cancer Inst, 2022, 114(2): 263-270.
12. Sharma R. Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990-2019: an examination using estimates from the global burden of disease 2019 study. Breast Cancer Res Treat, 2023, 202(3): 529-540.
13. 张馨, 吴羡美, 李虹, 等. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担. 实用肿瘤学杂志, 2023, 37(2): 107-111.
14. 胡志强, 游伟程, 潘凯枫, 等. 中、美两国癌症流行特征分析—《2023美国癌症统计报告》解读. 科技导报, 2023, 41(18): 18-28.
15. Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. JNCC, 2022, 2(1): 1-9.
16. Mahdavi M, Nassiri M, Kooshyar MM, et al. Hereditary breast cancer; Genetic penetrance and current status with BRCA. J Cell Physiol, 2019, 234(5): 5741-5750.
17. Łukasiewicz S, Czeczelewski M, Forma A, et al. Breast cancer—Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. Cancers (Basel), 2021, 13(17): 4287. doi: 10.3390/cancers13174287.
18. Huang YJ, Lee PH, Chen LC, et al. Relationships among green space, ambient fine particulate matter, and cancer incidence in Taiwan: a 16-year retrospective cohort study. Environ Res, 2022, 212(Pt C): 113416. doi: 10.1016/j.envres.2022.113416.
19. Niehoff NM, Terry MB, Bookwalter DB, et al. Air pollution and breast cancer: an examination of modification by underlying familial breast cancer risk. Cancer Epidemiol Biomarkers Prev, 2022, 31(2): 422-429.
20. Zupunski L, Yaumenenka A, Ryzhov A, et al. Breast cancer incidence in the regions of Belarus and Ukraine most contaminated by the Chernobyl accident: 1978 to 2016. Int J Cancer, 2021, 148(8): 1839-1849.
21. Landrigan PJ, Raps H, Cropper M, et al. The Minderoo-Monaco Commission on plastics and human health. Ann Glob Health, 2023, 89(1): 23. doi: 10.5334/aogh.4056.
22. 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范 (2021年版). 中国癌症杂志, 2021, 31(10): 954-1040.
23. 中国研究型医院学会乳腺专业委员会, 中国女性乳腺癌预防共识专家组. 中国女性乳腺癌预防专家共识. 中国研究型医院, 2022, 9(4): 5-13.
24. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA, 2015, 314(15): 1599-1614.
25. 李爱华, 叶研, 沈壮, 等. 北京市女性乳腺癌绝经前后危险因素分析. 现代预防医学, 2022, 49(13): 2492-2496.
26. 庞晶, 贾斌, 朱慧瑞, 等. 低浓度TBBPA长期暴露对乳腺癌细胞增殖效应研究. 山西大学学报 (自然科学版), [2023-12-14]. http://kns.cnki.net/kcms/detail/14.1105.n.20230708.2116.003.html.
27. Winters S, Martin C, Murphy D, et al. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci, 2017, 151: 1-32.
28. Lynch BM, Neilson HK, Friedenreich CM. Physical activity and breast cancer prevention. Recent Results Cancer Res, 2011, 186: 13-42.
29. Wang F, Liu L, Cui S, et al. Distinct effects of body mass index and waist/hip ratio on risk of breast cancer by joint estrogen and progestogen receptor status: results from a case-control study in Northern and Eastern China and implications for chemoprevention. Oncologist, 2017, 22(12): 1431-1443.
30. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press), 2019, 11: 151-164.
31. Jia T, Liu Y, Fan Y, et al. Association of Healthy Diet and Physical Activity With Breast Cancer: Lifestyle Interventions and Oncology Education. Front Public Health, 2022, 10: 797794. doi: 10.3389/fpubh.2022.797794.
32. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin, 2019, 69(3): 184-210.
33. Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst, 2014, 106(11): dju289. doi: 10.1093/jnci/dju289.
34. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med, 2005, 353(17): 1784-1792.
35. 何明艳, 朱碧琪, 钟媛, 等. 2005-2013年中国女性乳腺癌发病及死亡趋势分析. 中华疾病控制杂志, 2019, 23(1): 10-14.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Comparison of epidemiological characteristics and prevention of breast cancer in China and the United States

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content